Compare ASTRAZENECA PHARMA with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs VENUS REMEDIES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA VENUS REMEDIES ASTRAZENECA PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 117.1 -13.4 - View Chart
P/BV x 35.8 0.9 3,990.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
VENUS REMEDIES
Mar-18
ASTRAZENECA PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,278126 1,015.1%   
Low Rs88361 1,444.5%   
Sales per share (Unadj.) Rs228.4301.8 75.7%  
Earnings per share (Unadj.) Rs10.4-24.9 -41.7%  
Cash flow per share (Unadj.) Rs16.32.5 639.0%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.8293.3 33.7%  
Shares outstanding (eoy) m25.0012.34 202.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.70.3 1,526.7%   
Avg P/E ratio x104.2-3.8 -2,772.6%  
P/CF ratio (eoy) x66.436.7 180.8%  
Price / Book Value ratio x10.90.3 3,430.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0081,154 2,340.8%   
No. of employees `0001.40.9 146.6%   
Total wages/salary Rs m1,535393 390.6%   
Avg. sales/employee Rs Th4,210.94,026.1 104.6%   
Avg. wages/employee Rs Th1,132.2425.0 266.4%   
Avg. net profit/employee Rs Th191.1-331.8 -57.6%   
INCOME DATA
Net Sales Rs m5,7103,724 153.3%  
Other income Rs m12323 544.4%   
Total revenues Rs m5,8333,747 155.7%   
Gross profit Rs m463395 117.2%  
Depreciation Rs m147338 43.6%   
Interest Rs m0354 0.0%   
Profit before tax Rs m438-275 -159.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m17932 566.1%   
Profit after tax Rs m259-307 -84.4%  
Gross profit margin %8.110.6 76.5%  
Effective tax rate %40.8-11.5 -355.8%   
Net profit margin %4.5-8.2 -55.1%  
BALANCE SHEET DATA
Current assets Rs m3,2092,638 121.7%   
Current liabilities Rs m2,0702,305 89.8%   
Net working cap to sales %20.08.9 223.2%  
Current ratio x1.61.1 135.5%  
Inventory Days Days72135 53.4%  
Debtors Days Days3546 75.4%  
Net fixed assets Rs m7904,871 16.2%   
Share capital Rs m50123 40.5%   
"Free" reserves Rs m2,4193,496 69.2%   
Net worth Rs m2,4693,619 68.2%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m4,6057,509 61.3%  
Interest coverage xNM0.2-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.20.5 250.0%   
Return on assets %5.60.6 891.2%  
Return on equity %10.5-8.5 -123.7%  
Return on capital %17.71.6 1,121.2%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m3000-   
Fx outflow Rs m2,015517 390.1%   
Net fx Rs m-1,715-517 332.1%   
CASH FLOW
From Operations Rs m88514 17.1%  
From Investments Rs m-94-123 76.0%  
From Financial Activity Rs mNA-387 0.0%  
Net Cashflow Rs m-64 -135.7%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 166.7%  
FIIs % 15.7 0.6 2,706.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 66.4 13.7%  
Shareholders   12,856 20,121 63.9%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CIPLA  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 13, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - BIOCON COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS